Articles tagged "Monoclonal antibodies"

2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
Z. A. Yetmar¹, E. Beam¹, J. C. O'Horo¹, R. Ganesh², D. M. Bierle², L. Brumble³, M. T. Seville⁴, R. R. Razonable¹
¹Infectious Diseases, Mayo Clinic, Rochester, MN, ²General Internal Medicine, Mayo Clinic, Rochester, MN, ³Infectious Diseases, Mayo Clinic, Jacksonville, FL, ⁴Infectious Diseases, Mayo Clinic, Scottsdale, AZ
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…
2021 American Transplant Congress
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of At-1501
S. Perrin¹, A. Gill², C. Gill², P. Gustafson¹
¹Novus Therapeutics, Irvine, CA, ²ALS Therapy Development Institute, Cambridge, MA
*Purpose: Execute a phase 1 study of AT-1501 to assess safety, pharmacokinetics, and functional activity.*Methods: The study employed a placebo-controlled, sequential, dose-escalation design. 28 healthy…
2021 American Transplant Congress
Pharmacokinetic and Toxicity Studies of an Anti CD40L Antibody, At-1501 in Rhesus Macaques
S. Perrin¹, A. Gill², C. Gill², F. Vieira², K. Thompson²
¹Novus Therapeutics, Irvine, CA, ²ALS Therapy Development Institute, Cambridge, MA
*Purpose: CD40L is a costimulatory receptor for CD40 found on T helper cells. Binding of CD40L on T cells to CD40 on antigen presenting cells…
2021 American Transplant Congress
The Development and Characterization of AT1501, an Anti CD40L Antibody Lacking Fc Effector Function
S. Perrin¹, A. Gill², C. Gill², F. Vieira², K. Thompson², J. Lincecum², B. Jiang²
¹Novus Therapeutics, Irvine, CA, ²ALS Therapy Development Institute, Cambridge, MA
*Purpose: CD40L is a costimulatory type II membrane receptor for CD40. The binding of CD40L on T helper cells to CD40 on antigen presenting cells…
2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
W. Cochran¹, R. Avery², D. Brennan², N. Lawrence², A. Brown², S. Sullivan², B. Adams², M. McCarthy², S. Ellis², F. Naqvi², E. Kraus², N. Alachkar², S. Alasfar², F. Al Ammary², J. Horn², L. Hartman², L. Fessler², S. Purekal², Z. Siddiqui², D. Carter², J. Ficke², M. Kantsiper², L. Boyer², I. Gupta², A. Gurakar², D. Ostrander², J. Langlee², S. Shoham², K. Marr², P. Shah²
¹Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, ²Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
2021 American Transplant Congress
Bamlanivimab for Covid-19 in Kidney Transplant Patients
M. Y. Jan, S. El-Sayegh, M. S. Yaqub, D. P. Mishler, O. Adebiyi, M. D. Anderson, T. E. Taber, A. Sharfuddin
Nephrology, Indiana University School of Medicine, Indianapolis, IN
*Purpose: Treatment options for patients with COVID 19 have limited efficacy in reducing severity and duration of viral symptoms as well as progression to severe…
2020 American Transplant Congress
CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection
K. Doberer¹, J. Kläger², G. A. Gualdoni¹, K. Mayer¹, F. Eskandary¹, H. Agis³, T. Reiter¹, R. Reindl-Schwaighofer¹, M. Wahrmann¹, G. Cohen¹, H. Haslacher⁴, G. Bond¹, I. Simonitsch-Klupp⁵, I. Farkash⁶, P. Halloran⁷, G. A. Böhmig¹
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine I, Medical University of Vienna, Vienna, Austria, ⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁶Dept. of Pathology, University of Michigan, Ann Arbor, MI, ⁷Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Late antibody-mediated rejection (ABMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells (PC) and natural killer (NK) cells expressing…
2020 American Transplant Congress
Long Term Outcomes of Kidney Transplantation in Patients with AL-Amyloidosis – The Mayo Clinic Experience
A. Bentall¹, C. Heybali², J. Wen³, A. Hatem¹, C. A. Schinstock¹, E. Lorenz¹, M. El Ters¹, M. Mai⁴, H. Khamash⁵, D. Murray⁶, M. D. Stegall⁷, F. G. Cosio¹, M. P. Alexander⁶, N. Leung¹
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ²School of Medicine, Dokuz Eylul University, Izmir, Turkey, ³National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing, China, ⁴Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, ⁵Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ, ⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁷Department of Transplant Surgery, Mayo Clinic, Rochester, MN
*Purpose: New clone-directed therapies and better definition of hematological response criteria allows assessment of post-kidney transplantation outcomes in patients with light-chain (AL) amyloidosis*Methods: Patients with…
2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
R. M. Hofmann¹, J. Combs², K. J. Schmidt³, T. Dyckman⁴
¹Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, ²Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, ³Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, ⁴Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
2020 American Transplant Congress
Risk of Histological Relapse in Patients with Monoclonal Gammopathy of Renal Significance after Kidney Transplantation
A. Bentall¹, C. Heybeli², F. G. Cosio¹, M. El Ters¹, N. Leung¹, M. P. Alexander³
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Dokuz Eylul University, Izmir, Turkey, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
*Purpose: There is increased recognition of Monoclonal Gammopathy of Renal Significance (MGRS) but data on kidney transplant (ktx)outcomes are lacking. We assessed KTX outcomes of…